• Minoryx
    Minoryx
    Home
    Our Company
    Who we areManagement teamBoard of directorsScientific advisory boardFunding
    Our Science
    OverviewAdrenoleukodystrophyFriedreich's ataxia
    Our Programs
    OverviewLeriglitazone
    Clinical Studies
    Clinical Studies ADVANCEFRAMESNEXUSResourcesExpanded Access Policy
    Media
    Careers
    Follow us
    Contact
    Our company
    Home Our Company Who we are
  • Who we are

    Minoryx is a clinical-stage biotech company focused on the discovery and development of novel therapies for severe, orphan genetic diseases of the central nervous system (CNS) with high unmet medical need.

    Our lead program is a novel, selective and differentiated brain penetrant PPAR gamma agonist (leriglitazone), which is currently in clinical development for X-ALD and other CNS diseases. Leriglitazone demonstrated strong preclinical proof-of-concept in relevant animal models of disease and successfully completed phase 1 clinical trials. Leriglitazone was evaluated in a phase 2/3 study in adrenomyeloneuropathy (AMN) in EU and US with an open-label extension still ongoing. Leriglitazone significantly reduced the progression of cerebral lesions and myelopathy symptoms. The marketing authorization application (MAA) for adult male X-ALD patients is under review by the EMA and the launch preparations in the EU are underway. Also, discussions are currently ongoing with the FDA to define the next steps for its US approval path. In parallel, a separate study is ongoing on pediatric cALD patients in EU.

    Additionally, a proof of concept study in Friedreich’s Ataxia (FRDA) showed clinical benefit in this population and a phase 3 confirmatory study is under discussion with the  EMA and FDA.

    Leriglitazone has been granted Orphan Drug Designation for X-ALD and for FRDA by both the European Commission (EC) and the US Food and Drug Administration (FDA),  as well as, Fast Track for X-ALD from the US FDA. In addition, leriglitazone has been designated as Rare Pediatric Disease Designation by FDA for both X-ALD and FRDA.

  • Our values and how we make a difference:

    Commitment:

    One of the biggest assets of the company is our team, a group of professionals fully committed to the making new therapies available for patients suffering from severe, orphan diseases.

    Social responsibility:
    We are dedicated to bringing new hope for people suffering from rare diseases, especially children and their families.

    Innovation & Dynamism:
    We innovate by exploiting state-of-the art technologies. We form synergistic drug development partnerships and provide an environment which fosters creativity and open-mindedness.

    Added Value:
    We are making strides to provide life-changing treatments for diseases with high unmet medical needs.

  • TecnoCampus Mataró-Maresme
    Headquarters
    Offices
    info@minoryx.com +34 93 544 14 66
    Av. Ernest Lluch 32 - TCM3
    08302 Mataró (Barcelona) Spain
    I-Tech Incubator
    Belgian R&D Site
    Offices
    info@minoryx.com +32 787 00 162
    Rue Auguste Piccard 48, I - Tech Incubator
    6041 Gosselies (Charleroi) Belgium
  • Contact
    Headquarters
    https://www.minoryx.com/content/imgs/mail/logo.png
    Av. Ernest Lluch 32 - TCM3
    08302 Mataró
    (Barcelona) Spain
    info@minoryx.com 0034935441466+34 93 544 14 66
    Belgian R&D Site
    https://www.minoryx.com/content/imgs/mail/logo.png
    Rue Auguste Piccard 48, I - Tech Incubator
    6041 Gosselies
    (Charleroi) Belgium
    info@minoryx.com 003278700162+32 787 00 162
    Contact
    Follow us
    Legal Notice Privacy Policy Cookies Policy
    by eMascaró